Travecta Therapeutics

[Not Yet Scheduled]
Travecta is a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions by utilizing a natural transport system in the blood-brain barrier (“BBB”) as a novel delivery platform.

The Travecta platform technology came out of David Silver’s lab at Duke-NUS Medical School and is based on the discovery that the MFSD2A protein, in the BBB, can transport drugs into the CNS when attached to modified fatty acids. Travecta uses this platform to select and screen active drugs with poor BBB penetration and conjugate them with transport-enabling structures to facilitate BBB transport via MFSD2A and specific release of active drug in the CNS.

The Company’s lead program for early platform validation is for the treatment of pain, anxiety, and urinary tract dysfunction, and is slated to enter the clinic in Q4 2022. Pipeline programs in neuro-oncology and neuro-inflammation will see early preclinical validation in highly translatable models in late 2
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
Singapore
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
TVT-004 for pain, epilepsy, and urinary tract dysfunction
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided